Induction of apoptosis in oral squamous carcinoma cells by pyrrolo-1,5-benzoxazepines

KATE O'CALLAGHAN¹, ELEONORA PALAGANO², STEFANIA BUTINI³, GIUSEPPE CAMPIANI^{3,4}, D. CLIVE WILLIAMS², DANIELA M ZISTERER², and JEFF O'SULLIVAN¹.

¹School of Dental Science; ²School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland; ³Department of Drug Chemical Technology, University of Siena; ⁴European Research Centre for Drug Discovery and Development (NatSynDrugs), 53100 Siena, Italy.

DOI: 10.3892/mmr_xxxxxxx

Abstract. Oral cancer (OC) is a largely asymptomatic disease, 1 2 resulting in one of the highest mortality rates of any cancer. 3 OC is currently ranked as the sixth most common cancer in 4 the world, according to a recent World Health Organization 5 analysis, and its prevalence is increasing, both in western and developing regions. Depending on the stage of OC, treatment 6 7 strategies include surgery, radiation therapy and chemotherapy, or a combination thereof. As with numerous other 8 9 types of cancer, resistance to conventional chemotherapeutic 10 drugs is increasing in oral squamous cell carcinoma (OSCC). 11 The present study aimed to investigate the use of a novel group 12 of compounds, the pyrrolo-1,5-benzoxazepines (PBOXs), as 13 a therapeutic alternative for the treatment of OC. PBOXs are 14 microtubule-targeting agents that are able to induce apoptosis 15 in numerous cancer cell types, thereby preventing tumour cell proliferation. Ca9.22 gingival and TR146 buccal cell lines 16 17 were used as models for OSSC. Cell viability and proliferation in the presence of two PBOXs: PBOX-6 and PBOX-15, 18 was monitored using an AlamarBlueTM assay. Flow cytometric 19 20 analysis of propidium iodide-stained cells was used to deter-21 mine the DNA content, and therefore the percentage of cells 22 in each phase of the cell cycle. Microtubule disruption was 23 determined by indirect immunofluorescence staining. Changes 24 in protein expression and degradation were determined by 25 western blotting. The results of the present study indicated that 26 both PBOX-6 and -15 were able to induce apoptotic cell death 27 by disrupting the microtubule network in both cell lines. The 28 EC₅₀ values were subsequently calculated for both PBOX-6 29 and -15, and PBOX-15 was shown to possess a higher potency. 30 Both compounds displayed anti-proliferative effects mediated 31

Correspondence to: Dr Kate O'Callaghan, School of Dental Science, Trinity College Dublin, College Green, Lincoln Place, Dublin 2, Ireland E-mail: ocallaka@tcd.ie

E-mail: ocanaka@tcu.le

Key words: pyrrolo-1,5-benzoxazepines, microtubule-targeting agents, oral cancer

through sustained G_2/M arrest accompanied by tubulin disruption, and a decrease in DNA repair protein poly (ADP ribose) 33 polymerase expression. These findings suggest that PBOXs 34 may prove useful, either alone or in combination with other 35 agents, in the treatment of chemotherapeutic resistant OSCC. 36

37

38

39

Introduction

Oral cancer (OC) is the sixth most common cancer worldwide 40 and has one of the highest mortality rates, due to it being largely 41 asymptomatic until the latter stages of the disease. Cancers of 42 the oral cavity include cancers that occur in the tongue, floor 43 of the mouth, buccal mucosa, alveolus, retromolar trigone, 44 gingival, hard palate, and lips (1,2). A total of 90% of OCs 45 are squamous cell carcinomas (SCC) (3). SCC is caused by 46 the presence of malignant cells in the epithelium. Oral SCC 47 (OSCC) accounts for 2-3% of all malignancies, the prevalence 48 49 of which ranges between 1-10 cases per 100,000 people in the majority of countries (4). 50

OSCC prognosis is poor, with a 5-year survival rate of 51 ~50%, according to the National Cancer Research Institute (5). 52 Treatments for OSCC are usually limited to a combination of 53 chemotherapy and radiation, in order to reduce tumour size 54 55 prior to the surgical removal of the tumour margins. Two of the most common chemotherapeutic agents used in the 56 treatment of OSCC are cisplatin and 5-fluorouracil (6), and 57 recurrent tumours are usually treated with one of these two 58 chemotherapy drugs. However, resistance to these drugs may 59 develop following treatment, as is the case in numerous types 60 of cancer (7,8). 61

Pyrrolo-1,5-benzoxazepines (PBOXs) are a novel family 62 of compounds that have been shown to induce cell cycle 63 arrest and apoptosis in numerous cancer cell lines, including 64 chemotherapy-resistant cell lines (9,10). In addition, PBOXs 65 have been shown to induce cell apoptosis in ex vivo patient 66 samples and in in vivo animal models of breast cancer and 67 chronic myeloid leukaemia (10,11). Notably, PBOXs display 68 minimal toxicity towards normal blood and bone marrow 69 70 cells (12). A recently improved understanding regarding the 71 molecular mechanisms underlying the apoptotic effects of PBOX compounds has allowed their development as anti-72 neoplastic therapeutic agents. Within the PBOX family, two 73 members exhibit markedly elevated activity, PBOX-6 and
 PBOX-15 (Fig. 1) (10).

3 Mulligan et al (13) previously demonstrated that 4 PBOX-induced apoptosis in cancer cells is preceded by 5 a marked G_2/M phase cell cycle arrest, and that the cells 6 displayed morphological features that suggested an inhibi-7 tion of mitosis, notably in pro-metaphase. The effects of PBOXs on cell morphology are similar to those induced by 8 9 two microtubule-targeting drugs, paclitaxel and nocodazole, 10 which are polymerising and depolymerising agents, respectively. These results are concordant with previous studies that 11 also demonstrated that anti-microtubule agents arrest the cell 12 13 cycle in pro-metaphase (14,15).

14 Previous studies have suggested that PBOXs possess 15 anti-microtubule activity. Through indirect immunofluorescence analysis, Mulligan et al (13) demonstrated that 16 pro-apoptotic PBOX compounds result in depolymerisation of 17 the microtubule network, and an inhibition of the assembly 18 of purified tubulin in vitro. Tubulin has therefore been iden-19 20 tified as the molecular target of the pro-apoptotic PBOX 21 compounds (15).

22 In the present study the pro-apoptotic capabilities of two 23 representative members of the PBOX family, PBOX-6 and 24 PBOX-15, were examined in the TR146 (buccal mucosa) and 25 Ca9.22 (gingival carcinoma) cell lines. The aim of the present 26 study was to investigate the potential of these compounds on inhibiting the proliferation of OSCC cells. The present study 27 also examined the cell death mechanism and efficacy of the 28 29 compounds and aimed to determine the effectiveness of the 30 compounds against OSCC cells with differing genotypes. 31 Together, the results from the present study may indicate the 32 potential of the PBOX compounds in the treatment of OSCC, and whether there is in merit further investigation, either alone, 33 34 or in combination with other agents as a potential treatment 35 modality for OC. 36

37 Materials and methods

38

39 Reagents. All reagents were obtained from Sigma-Aldrich 40 (Arklow, Ireland) unless otherwise stated. The PBOX compounds, 7-[(N,N-dimethycarbomoyl) oxy]-6-(naphth-1-yl) 41 42 pyrrolo[2,1-d][1,5]benzoxazepine (PBOX-6), and 4-acetoxy-5-43 (naphth-1-yl)naphtho[2,3-b] pyrrolo[2,1-d][1,4]oxazepine 44 (PBOX-15), were synthesized as previously described (16). The 45 PBOX compounds were subsequently dissolved in 1% ethanol, 46 and stored at -20°C. The antibodies used in the present study were as follows: Mouse anti-human/rat/mouse anti-α-tubulin 47 (cat. no. CP06; EMD Millipore, Billerica, MA, USA); mouse 48 anti-human anti-poly (ADP ribose) polymerase (PARP; 49 50 cat. no. MABC547; Merck Biosciences Ltd., Nottingham, UK); and mouse anti-β-actin (cat. no MAB1501; EMD Millipore). 51 52

53 Cell culture. Both cell lines were maintained in a 95% 54 humidified atmosphere containing 5% CO₂ at 37°C, and all 55 cell culture experiments were carried out under sterile conditions in a laminar flow hood. Cell growth and viability were 56 57 visually monitored using a light microscope (Nikon Eclipse 58 TS100; MicronOptical, Wexford, Ireland) with 10 and 20x 59 dry objectives. The TR146 cell line was initially derived from 60 the neck node of a 67 year-old female (the primary tumour was located in the buccal mucosa) and was obtained from the 61 Health Protection Agency Culture Collection (Salisbury, UK). 62 The TR146 cells were maintained in Dulbecco's Modified 63 Eagle's medium, supplemented with 10% v/v foetal bovine 64 serum (FBS), 10 U/ml penicillin, 0.1 mg/ml streptomycin, 65 and 2 mM glutamine. The Ca9.22 cell line was obtained from 66 the Japanese Collection of Research Bioresources Cell Bank 67 (Osaka, Japan). The Ca9.22 cells were maintained in Minimum 68 Essential medium, supplemented with 10% v/v FBS, 10 U 69 penicillin, 0.1 mg/ml streptomycin, and 2 mM glutamine. All 70 control cells were treated with vehicle (1% ethanol) alone. 71

Cell proliferation. Cell proliferation was determined using 73 AlamarBlueTM dye (Life Technologies, Grand Island, 74 NY, USA), which allowed the visualisation of changes in 75 compound fluorescence that occur as a consequence of the 76 reduced number of viable, proliferating cells. The cells were 77 seeded in 96-well plates for each of the time points with speci-78 fied concentrations of PBOX-6 (10 nM-100 µM) or PBOX-15 79 (1 nM-250 μ M), and were incubated at 37°C in 5% CO₂. A 80 final concentration of 10% (v/v) AlamarBlueTM was added to 81 the cells 4 h prior to the end of each time point. Fluorescence 82 was measured at an excitation wavelength of 544 nm and at an 83 emission wavelength of 590 nm, using a SpectraMax Gemini 84 spectrofluorometric plate reader (Molecular Devices (UK) 85 Ltd, Wokingham, UK). Cell viability was determined as a 86 percentage of the vehicle-only cells. The experimental results 87 were displayed as dose-response curves and half maximal 88 effective concentration (EC₅₀) values, as determined using 89 Prism GraphPad 5 (GraphPad Software, Inc., La Jolla, CA, 90 USA). 91 92

Immunofluorescence. The cells were cultured for 24 h on 93 13 mm glass coverslips with the following seed densities: 94 Ca9.22, 3x10⁴ cells/coverslip; and TR146, 4x10⁴ cells/cover-95 slip. The cells were subsequently cultured in the presence 96 of either PBOX-6 or PBOX-15 for a further 24 h. Following 97 incubation, the cells were fixed with 4% paraformaldehyde in 98 phosphate-buffered saline (PBS) for 15 min, permeabilised 99 with 0.2% Triton in PBS for 10 min, rinsed with PBS, and 100 blocked using 1% bovine serum albumin (BSA) in PBS 101 containing Tween[®] 20 (PBST) for 30 min. The cells were 102 then incubated with the following primary antibodies: Mouse 103 anti-a-tubulin (1:1,000) in 1% BSA and PBST for 1 h, prior 104 to incubation with secondary goat anti-mouse antibody 488 105 (cat. no. a-11001; Life Technologies; 1:500) in 1% BSA and 106 PBST for 1 h. The coverslips were then placed on glass slides 107 with 3.5 μ l VectashieldTM mounting medium (Vector Labs, 108 Burlingame, CA, USA) containing the nuclear counterstain 109 4,6-diamidino-2-phenylindole (DAPI), and stored in the 110 dark at 4°C until imaging. The indirect fluorescence of the 111 cells was examined using a standard filter set for DAPI and 112 blue/green, through 10 and 20x dry objectives, and a 60x oil 113 objective using a Zeiss Axiovert/Axiocam CCD system, and 114 imaged using AxioVision AxioVs40 software (Carl Zeiss 115 Ltd., Cambridge, UK). 116

117

72

DNA content. The cellular DNA content was determined 118 using of propidium iodide (PI), an intercalating fluorescent 119 dye. The fluorescence intensity is proportional to the quantity 120

61

62

63

64

65

66

67

68

69

70

71 72

73

74

75

76

77 78


79

88

94

95

96



1




Figure 1. Chemical structures of pyrrolo-1,5-benzoxazepine (PBOX)-analogues PBOX-6 and PBOX-15.

20 of DNA present in the cell. Both cell lines were cultured in 21 the presence of PBOX-6 or PBOX-15 at the desired concen-22 trations and time points. The cells were then harvested by 23 trypsinisation, prior to being centrifuged at 220 x g for 5 min, 24 washed with PBS, and centrifuged once more. The super-25 natant was decanted and the cell pellets were resuspended 26 in 200 μ l PBS, prior to the addition of 2 ml ice-cold 70% 27 ethanol in order to fix the cells. Following overnight fixation at 4°C, the cells were centrifuged at 200 x g for 5 min in 28 29 order to remove the ethanol, and the pellet was resuspended 30 in 400 μ l PBS, followed by 25 μ l RNase A, and 75 μ l PI. The cells were incubated in the dark at 37°C for 30 min. 31 The samples were subsequently transferred to appropriately 32 33 labeled fluorescence activated cell sorting (FACS) tubes, 34 and were analysed using a FACSCalibur flow cytometer 35 (BD Biosciences, Oxford, UK). The fluorescent signal was detected using a 630-22 nm band pass filter (FL2). The cell 36 37 lines were gated in order to prevent cell debris and doublets from being counted. A total of >10,000 cells were counted 38 39 and analysed using Treestar FlowJo v10 (FlowJo, Oregon, 40 OR, USA).

41

42 Analysis of protein expression by western blotting. The cells cultured in the presence of PBOX-6 or PBOX-15 for 24, 48, 43 and 72 h, were harvested and centrifuged at 220 x g for 5 min, 44 following which the supernatants were discarded and the cell 45 pellets were resuspended in 2 ml ice-cold PBS. Following 46 further centrifugation at 220 x g for 5 min, the supernatant 47 was removed and the pellets were resuspended in 80 μ l 48 49 ice-cold lysis buffer (150 mM sodium chloride, 1.0% Triton 50 X-100, 50 mM Tris; pH 8.0) containing Complete Protease 51 Inhibitor Cocktail (Roche Diagnostics Ltd., Burgess Hill, 52 UK). The samples were maintained under constant agitation 53 at 1,000 rpm for 30 min at 4°C, prior to being centrifuged at 54 13,000 x g for 20 min at 4°C. The supernatants were aspi-55 rated and placed in an eppendorf tube on ice until further 56 experimentation. The protein concentrations were deterxw-57 mined using a bicinchoninic acid assay. The protein samples 58 were separated by SDS-PAGE with an 8% resolving gel. The 59 proteins were then transferred to a polyvinylidene difluoride 60 (PVDF) membrane using a semi-dry blotter for 1 h. The PVDF membranes were subsequently blocked with 5% non-fat milk, 80 and probed with the appropriate primary antibodies prior 81 to being incubated with horseradish peroxidase-conjugated 82 goat anti-mouse secondary antibody (cat. no. sc2031; Santa 83 Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Protein 84 expression was visualised through chemiluminescence using 85 an Immobilon Western Chemiluminescent HRP substrate 86 (Merck Millipore, Darmstadt, Germany). 87

Statistical analysis. Statistical significance was determined 89 using Prism GraphPad 5 (GraphPad Software, La Jolla, CA, 90 USA). Analysis was performed using an unpaired t-test with 91 post-hoc Bonferroni analysis. P<0.001 was considered to 92 indicate a statistically significant difference. 93

Results

PBOX compounds reduce OC cell proliferation. The OSCC 97 cell lines were treated for 72 h with PBOX-6 or PBOX-15 at 98 various concentrations. Cell proliferation was subsequently 99 measured using AlamarBlueTM assay. The results of the assay 100 indicated that PBOX-6 and PBOX-15 reduced proliferation of 101 both the Ca.922 and the TR146 cell lines in a dose-dependent 102 manner (Fig. 2). PBOX-15 was the more potent of the two 103 analogues. After 72 h, the EC₅₀ values of PBOX-6 and 104 PBOX-15 were 35 \pm 2.7 μ M and 470 \pm 86 nM for the TR146 105 cells, and 2.6 \pm 1 µM and 83 \pm 32 nM for the Ca9.22 cells, 106 respectively (Table I). The drug concentrations used for the 107 remaining experiments were chosen according to the results 108 of this cell proliferation assay. 109

110

PBOX compounds destabilise and depolymerise the micro- 111 tubule network in OC cells. The Ca9.22 and TR146 cells 112 were treated with either PBOX-6 or PBOX-15 for 24 h. 113 In addition, the cells were also treated with the known 114 tubulin polymeriser, paclitaxel (1 μ mol; 24 h), and the 115 tubulin depolymeriser, nocodazole (10 μ mol; 24 h), both 116 purchased from Sigma-Aldrich, which served as positive 117 controls. Immunofluorescent staining was used to detect 118 morphological changes in the microtubule network, such 119 as alterations in microtubule organisation and arrangement 120 Table I. Half maximal effective concentration (EC_{50}) values obtained for each pyrrolo-1,5-benzoxazepine (PBOX) compound in




Figure 2. Pyrrolo-1,5-benzoxazepines (PBOX)-6 and PBOX-15 reduce the viability of oral squamous cell carcinoma (OSCC) cell lines. OSCC cell lines. (A and B) TR146 and (C and D) Ca9.22 were treated with a range of (A and C) PBOX-6 and (B and D) PBOX-15 for 24, 48, and 72 h. AlamarBlueTM was added 4 h prior to endpoint reading. Fluorescence was measured using a Spectramax Gemini Plate reader at excitation and emission wavelengths of 544 nm and 590 nm, respectively. The values are presented as the mean ± standar error of the mean for three independent experiments.
 102
 103

103 104 105

61


(Fig. 3). In the vehicle TR146 (Fig. 3A) and Ca9.22 (Fig. 3B) 46 cells, the microtubule network was organised as cytoplasmic 47 tubulin filaments radiating from a central point to the 48 periphery. Exposure of the cells to the tubulin polymerising 49 50 agent paclitaxel resulted in a highly concentrated accumu-51 lation of filaments in dense peripheral bundles, indicative of microtubule stabilisation. Conversely, exposure to the 52 53 tubulin depolymerising agent nocodazole resulted in diffuse 54 tubule staining with no definition of structure caused by 55 microtubule disassembly. No alterations in microtubule structure were evident following treatment with a low dose 56 of 100 nM PBOX-6 and PBOX-15, whereas higher doses of 57 10 μ M PBOX-6 and 1 μ M PBOX-15 resulted in a change in 58 59 tubulin morphology resembling that induced by nocodazole. 60 These results indicate that PBOX compounds destabilise the microtubule network in a similar manner to a depolymerising 106 agent, in both TR146 and Ca9.22 cell lines. 107

In order to confirm the results of previous studies, namely 108 that the disruption observed using a confocal microscope is 109 the result of depolymerisation of the tubulin network, tubulin 110 polymerisation assays were performed using western blotting 111 (Fig. 3C). Following 4 h treatment with 10 μ M PBOX-6 or 112 1 μ M PBOX-15, tubulin was shown to be completely depo-113 lymerised in both cell lines. Following 4 h treatment with 114 paclitaxel, tubulin was polymerised, whereas treatment with 115 nocozadole resulted in unpolymerised tubulin. Treatment 116 with the vehicle (1% EtOH) resulted in equal amounts of 117 polymerised to unpolymerised tubulin. These results indicate 118 that the disruption observed by confocal microscopy was 119 indeed depolymerisation of the tubulin network. 120

1

44

45




(OSCC) cell lines. (A) TR146 and (B) Ca9.22 cells were treated with either vehicle, 1 µM paclitaxel (Tax), 10 µM nocodazole (Noc), 100 nM, 1 µM or 10 µM PBOX-15, or 100 nM, 1 µM or 10 µM PBOX-6 for 24 h. The medium was subsequently removed and the cells were fixed with paraformaldehyde. The cells were then incubated with monoclonal anti-a-tubulin antibody, followed by further incubation with fluorescein isothiocyanate-conjugated anti-mouse secondary antibody. The organization of the microtubule network (green) and the cellular DNA (blue) was visualized using a Zeiss Axiovert/Axiocam CCD system through 10x and 20x dry objectives, and a 60x oil objective. Scale bar, 20 µm. (C) In order to confirm tubulin depolymerisation in the TR146 and Ca9.22 cell lines, the cells were treated for 4 h with either vehicle (1% (v/v) ethanol), PBOX-6 (10 µM), PBOX-15 (1 µM), Tax (1 µM), or Noc (10 µM). The polymerised (P) or unpolymerised (U) tubulin was then separated by centrifugation in a microtubule-preserving buffer. The ratio of polymerised, vs. unpolymerised tubulin was subsequently assessed by western blot analysis using monoclonal antibodies directed against tubulin and loading control β-actin, followed by incubation with horseradish peroxidase-conjugated anti-mouse antibody. The images are representative of experiments repeated three times.

PBOX compounds induce G_2/M arrest and apoptosis in OC cells. The DNA content of the PI-stained TR146 and Ca9.22 cells was measured using flow cytometric analysis, thus allowing the successful identification of cell cycle arrest or apoptosis. A decrease in the number of cells in the G_2/M phase of the cell cycle was observed in both cell lines following 8h treatment with PBOX-6 (10 μ M) and PBOX-15 (1 μ M) (Fig. 4C and 4D). A marked decrease was observed in the number of TR146 cells arrested in G₂/M phase following 72 h treatment, 15.4±1.07% and 12.6±1.87% for PBOX-6 and -15, respectively. A significant decrease also occurred in the number of Ca9.22 cells arrested in the G_2/M phase following 72 h of treatment, 22.23±0.95% and 16.6±1.25% for PBOX-6 and PBOX-15, respectively. This decline in the levels of G2/M phase cells correlated with a marked increase in the number of apoptotic TR146 cells, with the levels of apoptosis rising to 4.4±1.210% in the control cells, 57.6 \pm 8.1% in the cells treated with 10 μ M PBOX-6, and 39.1 \pm 6.6% in the cells treated with 1 μ M PBOX-15 (Fig 4A and 4B). Similarly, in the Ca9.22 cell line, the number of cells in the sub- G_0/G_1 phase following 72 h increased to 2.120±0.8% in the control cells, 40.84±0.8% in the cells treated with PBOX-6, and 30.45±1.56% in the cells treated with PBOX-15. A decrease in the number of cells in the G2/M phase of the cell cycle were observed in each cell line following 8 h treatment with PBOX-6 (10 µM) and PBOX-15 (1 µM; Fig. 4C and 4D).

PBOX compounds induce degradation of PARP in OC cell lines. In order to confirm that the cell death observed during flow cytometric analysis was indeed cellular apoptosis, PARP degradation, which is associated with controlled cell death, was assessed. Concordant with the DNA content analysis results, 100 both PBOX-6 (10 μ M) and PBOX-15 (1 μ M) induced a decrease 101 in the expression levels of full length PARP in Ca9.22 and TR146 102 cells following 72 h treatment (Fig. 4E and 4F). Treatment with 103 the vehicle (1% (v/v) EtOH) did not affect PARP expression 104 in either cell line. In the TR146 cell line, PARP degradation 105 was observed following 24 h treatment with 1 μ M PBOX-15, 106 as compared with the vehicle control. PARP degradation was 107 clearly observed in the TR146 cell line following 48 h treatment 108 with both PBOX compounds. In addition, PARP degradation 109 was also observed in the Ca9.22 cell line following 48 h treat- 110 ment with both PBOX compounds. β -actin was used as a loading 111 control in all experiments. These results indicate that the PBOX 112 compounds induce apoptosis via tubulin disassembly.

Discussion

The present study assessed a novel set of compounds with 117 regards to their potential therapeutic value in OC. PBOX-15 118 and PBOX-6 are potent pro-apoptotic members of the PBOX 119 family, and have previously been shown to induce apoptosis 120



27 Figure 4. Pyrrolo-1,5-benzoxazepines (PBOX)-6 and PBOX-15 reduced proliferation of TR146 and Ca9.22 cells through induction of G₂/M cell cycle arrest 87 and cellular apoptosis. The TR146 and Ca9.22 cells were treated with 10 µM PBOX-6, and 1 µM PBOX-15 at various time points for up to 72 h. The values 88 28 are presented as the mean \pm standard error of the mean for three independent experiments. (A and B) Cells in the sub-G₀/G₁ phase with <2N quantities of 29 89 DNA were considered to be apoptotic, (C and D) whereas cells with 4N quantities of DNA were considered to be in the G_2/M phase of the cell cycle. PBOX-6 30 90 and PBOX-15 reduced full length poly (ADP ribose) polymerase (PARP) in Ca9.22 and TR146 cells. Both cell lines were treated with either vehicle (1% (v/v) 31 91 EtOH), 10 µM PBOX-6, or 1 µM PBOX-15 for the indicated times. (E and F) PARP degradation was assessed by western blot analysis using monoclonal antibodies targeting PARP, or loading control β -actin, followed by horseradish peroxidase (HRP)-conjugated anti-mouse secondary antibodies. The blots are 32 92 representative of experiments repeated three times. 33 93

35

in numerous human tumour cell lines, and to have anti-cancer
properties in various cell culture systems, animal models, and
clinical samples (11,17). In addition to inducing apoptosis in
various cancer cell types, PBOX-6 and -15 possess the added
benefit of inducing cytotoxicity in multi drug-resistant cancer
cells (18).

The present study demonstrated that PBOX compounds 42 were capable of reducing the proliferation of OC cell lines 43 TR146 and Ca9.22, with EC₅₀ values of $35\pm2.7 \ \mu$ M and 44 45 $2.6\pm1 \mu$ M for PBOX-6, and 470 ± 86 nM and 83 ± 32 nM for PBOX-15. These values are within a range previously observed 46 in other cancer cell lines exposed to PBOX compounds, 47 including K562 chronic myeloid leukemia cells, A2780 48 49 ovarian carcinoma cells, and various cancerous mammary 50 cells (9,16,17). PBOX-15, as previously reported, is the more 51 potent of the two compounds, a result that was confirmed in the present study in both cell lines tested, as demonstrated by 52 53 the order of magnitude of difference in the calculated EC_{50} 54 values. Significant variation in the sensitivity of each cell type 55 to PBOX treatment was also observed. The Ca9.22 gingiva cell line was sensitive to both PBOX-15 and PBOX-6, and 56 had significantly lower EC550 values, as compared with the 57 TR146 buccal cell line. The observed variation in efficacy 58 59 of the PBOXs in the two experimental cell lines suggests a 60 phenotypic or genotypic factor may be involved. In OSCC, ~50% of cases are associated with a mutation in the p53 gene, 96 which results in deleterious phenotypic manifestations and 97 impaired p53 function. The Ca9.22 cells have a known p53 98 mutation (19), whereas the TR146 cells have no known p53 99 mutation. Previous studies have reported the influence of p53 100 in modifying drug efficacy and function in cancer cells (20,21). 101

94

95

The disassembly of the microtubule network in other 102 cancer cell lines following treatment with PBOX-6 and 103 PBOX-15 suggested that the compounds act as microtubule 104 depolymerizing agents (13). To examine this hypothesis in 105 OSCC, the Ca9.22 and TR146 cells were treated with various 106 concentrations of PBOX-6 and PBOX-15. The results of the 107 present study were concordant with previous studies, demon- 108 strating that both PBOX compounds caused disassembly of 109 tubulin following 24 h treatment in vitro (13,22). In the case 110 of the control compounds, nocodazole depolymerised tubulin, 111 whereas treatment with paclitaxel resulted in tubulin aggrega- 112 tion through polymerisation. PBOX-15, the more potent of the 113 two compounds, was effective at disrupting tubulin at $1 \,\mu$ M in 114 both cell lines, whereas PBOX-6-mediated depolymerisation 115 was only observed at concentrations of 10 μ M. 116

This inhibition of tubulin assembly is likely to be the 117 cause of cell death following treatment with the PBOX 118 compounds (13). Tubulin is a key protein in spindle forma- 119 tion during the cell cycle. A mechanism known as the spindle 120

assembly checkpoint is activated during metaphase in the 1 2 cell cycle (23). In the presence of tubulin breakdown and loss 3 of spindle tension, the cell will not be able to continue into 4 anaphase. In order to determine part of the mechanism under-5 lying the response of OSCC cells to PBOX treatment, the effects 6 of PBOX-6 and PBOX-15 on the cell cycle were examined. The 7 PBOXs caused a time-dependent accumulation of cells in G₂/M phase, as early as 4 h in TR146 cells, and 8 h in Ca9.22 cells. This 8 0 was followed by an increase in the number of cells in sub- G_0/G_1 10 phase, indicative of apoptosis and a concomitant decrease in the percentage of cells in G_2/M . To confirm the mechanism of cell 11 death, degradation of the DNA repair enzyme PARP, which is 12 13 indicative of apoptosis, was examined. A decrease in the expres-14 sion levels of the full-length 116 kDa PARP was evident in both cell lines following treatment with both compounds after 72 h, 15 suggesting PARP had been cleaved. The decrease in full-length 16 PARP in the Ca9.22 cell line was more prominent than in the 17 TR146 cell line, demonstrating an increased sensitivity of the 18 Ca9.22 cells to the compounds as it also increased the EC_{50} 19 20 values obtained using this cell line. 21 The results of the present study indicated that PBOX-6, and its more potent analogue PBOX-15, may prove effective in the

22 treatment of OSCC. The present study has shown that PBOX-6 23 24 and PBOX-15 depolymerise their molecular target, tubulin, 25 resulting in cell death through apoptosis in OSCC cell lines. Given the prevalence of OSCC, the use of PBOX compounds 26 as topical agents may be a potential therapeutic strategy for this 27 disease. PBOX compounds used alone or in combination with 28 29 other antineoplastic agents may prove useful in the treatment 30 of OSCC.

32 Acknowledgements

The authors of the present study are thankful to the Dublin Dental University Hospital and Trinity College Dublin for funding this study through the 1252 initiative. An abstract describing this work was presented at the 23rd Biennial Congress of the European Association for Cancer Research.

References

40 41

39

31

33

- 42 1. Zhang L, Zhou X, Yao X, Wu Y and Zhang Q: Oral tongue cancer patients show a better overall survival than base of tongue cancer patients. J Cancer Res Clin Oncol 138: 341-346, 2012.
- 2. Arosarena OA, Madsen M and Haug R: Special considerations with floor of mouth and tongue cancer. Oral Maxillofac Surg Clin North Am 18: 521-531, 2006.
- 3. Beenken SW and Urist MM: Head and Neck Tumors. Current surgical diagnosis and treatment. L.W. Way, G.M. Doherty (Eds.). Lange Medical Books/McGraw-Hill, New York. 282-297, 2003.
- 4. World Health Organisation: World Cancer Report 2008.

- 5. National Cancer Research Institute: Surveillance, Epidemiology, 61 and End Results (SEER) program- 2004.
- Andreadis C, Vahtsevanos K, Sidiras T, Thomaidis I, Antoniadis K and Mouratidou D: 5-Fluorouracil and cisplatin in the treatment of advanced oral cancer. Oral Oncol 39: 380-385, 2003.
 Collumni L, Senerilla L, Visela L, et al. Malambaraneo femine et al.
- Galluzzi L, Senovilla L, Vitale I, *et al*: Molecular mechanisms of cisplatin resistance. Oncogene 31: 1869-1883, 2012.
- Zhang N, Yin Y, Xu SJ and Chen WS: 5-Fluorouracil: Mechanisms of resistance and reversal strategies. Molecules 13: 1551-1569, 2008.
 Netheric CM, Davie C, Torregue C, Standard M, Standa
- Nathwani SM, Butler S, Fayne D, et al: Novel 69 microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce apoptosis in multi-drug-resistant cancer cells. Cancer Chemother Pharmacol 66: 585-596, 2010.
 McElly of Alexandre States and States and
- McElligott AM, Maginn EN, Greene LM, *et al*: The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia. Cancer Res 69: 8366-8375, 2009.
- Bright SA, McElligott AM, O'Connell JW, *et al*: Novel 75 pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells *in vitro*, in *ex vivo* patient samples and *in vivo*. Br J Cancer 102: 1474-1482, 2010.
- Maginn EN, Browne PV, Hayden P, *et al*: PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cells. Br J Cancer 104: 281-289, 2011.
- Li YM and Broome JD: Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res 59: 776-780, 1999.
- 14. Woods CM, Zhu J, McQueney PA, Bollag D and Lazarides E: Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med 1: 506-526, 1995.
 83
 84
 85
- 15. Mulligan JM, Greene LM, Cloonan S, *et al*: Identification of tubulin as the molecular target of proapoptoticpyrrolo-1,5-ben-zoxazepines. Mol Pharmacol 70: 60-70, 2006.
 16. Grans LM, Fl. et al. 2017.
- 16. Greene LM, Fleeton M, Mulligan J, *et al*: The pyrrolo-1,5-ben-zoxazepine, PBOX-6, inhibits the growth of breast cancer cells *in vitro* independent of estrogen receptor status and inhibits breast tumour growth *in vivo*. Oncol Rep 14: 1357-1363, 2005.
 88
 90
- 17. Nathwani SM, Cloonan SM, Stronach M, *et al*: Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce cell cycle arrest and apoptosis in prostate cancer cells. Oncol Rep 24: 1499-1507, 2010.
 93
- Mc Gee MM, Campiani G, Ramunno A, *et al*: Activation of the c-Jun N-terminal kinase (JNK) signaling pathway is essential during PBOX-6-induced apoptosis in chronic myelogenous leukemia (CML) cells. J Biol Chem 277: 18383-18389, 2002.
- 20. Bunz F, Hwang PM, Torrance C, *et al*: Disruption of p53 in 100 human cancer cells alters the responses to therapeutic agents. 101 J Clin Invest 104: 263-269, 1999.
- Jackson JG, Pant V, Li Q, Chang LL, Quintas-Cardama A, 102 Garza D, Tavana O, Yang P, Manshouri T, Li Y, El-Naggar AK, 103 and Lozano G: p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. 104 Cancer Cell 21, 793-806, 2012. 105
- 22. Verma, NK, Dempsey E, Conroy J, et al: A new microtubule-targeting compound PBOX-15 inhibits T-cell migration via post-translational modifications of tubulin. J Mol Med 86, 457-469. 2008.
- 23. Rudner AD and Murray AW: The spindle assembly checkpoint. 109 Curr Opin Cell Biol 8: 773-780, 1996. 110
 - ULL
 - 111 112
 - 113
 - 114
 - 115
 - 116
 - 117
 - 118
 - 119 120

59 60

51

52

53

54

55

56

57

58